168 related articles for article (PubMed ID: 21212059)
1. A prospective evaluation of C-reactive protein levels and colorectal adenoma development.
Gunter MJ; Cross AJ; Huang WY; Stanczyk FZ; Purdue M; Xue X; Schoen R; Limburg PJ; Schatzkin A; Sinha R; Hayes RB
Cancer Epidemiol Biomarkers Prev; 2011 Mar; 20(3):537-44. PubMed ID: 21212059
[TBL] [Abstract][Full Text] [Related]
2. C-reactive protein and risk of colorectal adenomas or serrated polyps: a prospective study.
Crockett SD; Mott LA; Barry EL; Figueiredo JC; Burke CA; Baxter GJ; Sandler RS; Baron JA
Cancer Prev Res (Phila); 2014 Nov; 7(11):1122-7. PubMed ID: 25145487
[TBL] [Abstract][Full Text] [Related]
3. Serum CRP and IL-6, genetic variants and risk of colorectal adenoma in a multiethnic population.
Ognjanovic S; Yamamoto J; Saltzman B; Franke A; Ognjanovic M; Yokochi L; Vogt T; Decker R; Le Marchand L
Cancer Causes Control; 2010 Jul; 21(7):1131-8. PubMed ID: 20333461
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of pro-inflammatory markers plasma C-reactive protein and urinary prostaglandin-E2 metabolite in colorectal adenoma risk.
Davenport JR; Cai Q; Ness RM; Milne G; Zhao Z; Smalley WE; Zheng W; Shrubsole MJ
Mol Carcinog; 2016 Aug; 55(8):1251-61. PubMed ID: 26333108
[TBL] [Abstract][Full Text] [Related]
5. Plasma Inflammatory Markers and Risk of Advanced Colorectal Adenoma in Women.
Song M; Mehta RS; Wu K; Fuchs CS; Ogino S; Giovannucci EL; Chan AT
Cancer Prev Res (Phila); 2016 Jan; 9(1):27-34. PubMed ID: 26511487
[TBL] [Abstract][Full Text] [Related]
6. [C-reactive protein level and colorectal adenoma].
Park SK; Park DI; Park JH; Kim HJ; Cho YK; Sohn CI; Jeon WK; Kim BI; Kim JE; Son HJ
Korean J Gastroenterol; 2008 Apr; 51(4):225-31. PubMed ID: 18516001
[TBL] [Abstract][Full Text] [Related]
7. Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial.
Weissfeld JL; Schoen RE; Pinsky PF; Bresalier RS; Church T; Yurgalevitch S; Austin JH; Prorok PC; Gohagan JK;
J Natl Cancer Inst; 2005 Jul; 97(13):989-97. PubMed ID: 15998952
[TBL] [Abstract][Full Text] [Related]
8. Serum IGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma.
Gao Y; Katki H; Graubard B; Pollak M; Martin M; Tao Y; Schoen RE; Church T; Hayes RB; Greene MH; Berndt SI
Int J Cancer; 2012 Jul; 131(2):E105-13. PubMed ID: 21932422
[TBL] [Abstract][Full Text] [Related]
9. A prospective evaluation of C-peptide levels and colorectal adenoma incidence.
Murphy N; Cross AJ; Huang WY; Rajabzadeh-Heshejin V; Stanczyk F; Hayes R; Gunter MJ
Cancer Epidemiol; 2015 Apr; 39(2):160-5. PubMed ID: 25592235
[TBL] [Abstract][Full Text] [Related]
10. C-reactive protein and colorectal adenoma in the CLUE II cohort.
Tsilidis KK; Erlinger TP; Rifai N; Hoffman S; Hoffman-Bolton J; Helzlsouer KJ; Platz EA
Cancer Causes Control; 2008 Aug; 19(6):559-67. PubMed ID: 18214695
[TBL] [Abstract][Full Text] [Related]
11. C-reactive protein and colorectal adenomas: Self Defense Forces Health Study.
Otake T; Uezono K; Takahashi R; Fukumoto J; Tabata S; Abe H; Tajima O; Mizoue T; Ohnaka K; Kono S
Cancer Sci; 2009 Apr; 100(4):709-14. PubMed ID: 19469014
[TBL] [Abstract][Full Text] [Related]
12. Hormone replacement therapy, reproductive history, and colorectal adenomas: data from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial (United States).
Purdue MP; Mink PJ; Hartge P; Huang WY; Buys S; Hayes RB
Cancer Causes Control; 2005 Oct; 16(8):965-73. PubMed ID: 16132805
[TBL] [Abstract][Full Text] [Related]
13. Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients.
Groblewska M; Mroczko B; Wereszczyńska-Siemiatkowska U; Kedra B; Lukaszewicz M; Baniukiewicz A; Szmitkowski M
Clin Chem Lab Med; 2008; 46(10):1423-8. PubMed ID: 18844497
[TBL] [Abstract][Full Text] [Related]
14. Markers of systemic inflammation and colorectal adenoma risk: Meta-analysis of observational studies.
Godos J; Biondi A; Galvano F; Basile F; Sciacca S; Giovannucci EL; Grosso G
World J Gastroenterol; 2017 Mar; 23(10):1909-1919. PubMed ID: 28348498
[TBL] [Abstract][Full Text] [Related]
15. C-reactive protein levels are not associated with increased risk for colorectal cancer in women.
Zhang SM; Buring JE; Lee IM; Cook NR; Ridker PM
Ann Intern Med; 2005 Mar; 142(6):425-32. PubMed ID: 15767620
[TBL] [Abstract][Full Text] [Related]
16. C-reactive protein and the risk of incident colorectal cancer.
Erlinger TP; Platz EA; Rifai N; Helzlsouer KJ
JAMA; 2004 Feb; 291(5):585-90. PubMed ID: 14762037
[TBL] [Abstract][Full Text] [Related]
17. The association between location, age and advanced colorectal adenoma characteristics: a propensity-matched analysis.
Pommergaard HC; Burcharth J; Rosenberg J; Raskov H
Scand J Gastroenterol; 2017 Jan; 52(1):1-4. PubMed ID: 27686516
[TBL] [Abstract][Full Text] [Related]
18. Circulating Fibroblast Growth Factor-21 and Risk of Metachronous Colorectal Adenoma.
Florea A; Harris RB; Klimentidis YC; Kohler LN; Jurutka PW; Jacobs ET
J Gastrointest Cancer; 2021 Sep; 52(3):940-946. PubMed ID: 32918272
[TBL] [Abstract][Full Text] [Related]
19. Association of Colonoscopy Adenoma Findings With Long-term Colorectal Cancer Incidence.
Click B; Pinsky PF; Hickey T; Doroudi M; Schoen RE
JAMA; 2018 May; 319(19):2021-2031. PubMed ID: 29800214
[TBL] [Abstract][Full Text] [Related]
20. A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in U.S. men.
Giovannucci E; Rimm EB; Stampfer MJ; Colditz GA; Ascherio A; Kearney J; Willett WC
J Natl Cancer Inst; 1994 Feb; 86(3):183-91. PubMed ID: 8283490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
